Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here’s an interesting exercise. Let’s just take an historical viewpoint. How would you have thought of the future growth of this sector five years ago? How about 10 years ago? How about 15 or 20 years ago? One thing is certain - we sure have come a long way. and I think the majority of people here wouldn’t have conceived we’d get to this point 10 or 15 years ago.
I think we’re much closer to full legalization than we’ve ever been before. And that bodes well for the sector overall. The key is to invest in companies that have a needed product, excellent R&D, capable of keeping their expenses in check, and led by management capable of executing well without too much dilution. And management that is fully invested in the long term appreciation of their own shares.
Politicians taking matters into their own
Hands.
Cuomo signs NY hemp law; decision on extracts in food, beverages deferred
https://hempindustrydaily.com/cuomo-signs-ny-hemp-law-decision-on-extracts-in-food-beverages-deferred/
New York Gov. Andrew Cuomo signed a bill into law Monday that sets up a regulatory framework for the production and sale of hemp and hemp extracts in the state.
According to a statement from the governor’s office, the new law also requires hemp businesses to test and properly label products to safeguard consumers.
The law:
Gives the state Department of Agriculture and Markets jurisdiction over hemp growers.
Grants the Department of Health authority over hemp extracts.
Requires sellers of hemp extract products to be registered with the state.
Makes regulatory changes to ensure New York’s program conforms to the 2018 Farm Bill.
Defers any decisions about whether hemp extracts, including CBD, can be added to food and beverages.
“By establishing a regulatory framework for producing and selling hemp and hemp extract, we can set the industry on a path to continued growth in a smart, safe way that empowers both farmers and consumers,” Cuomo said in a statement.
Cuomo also said the state plans to conduct a hemp summit in January with the goal of doing more work on hemp industry policies.
Can a class action suit bring brought against the fda? Can CBD sue them?
You ever see a dog out in a yard by itself chasing its tail. It's such a funny site. Like don't they know it's THEIR tail?
Oftentimes they chase their tails because they are a bored; it’s a way for them to have fun and expend some energy. This is especially true for puppies, who may not even realize that their tail is actually a part of their body,
Too funny.
Oftentimes puppy retail investors chase their tails in trying to understand the lack of news from the company they/'re invested in.
Thanks, deez! And a great question that never got point that I'd like to get insight into: It appears they are identifying exactly what part of the body you can take a stem cell from to most effectively treat specific conditions.
Dumbing down the post by Thomas. I am by no means an expert in the field but I am an ICU nurse and have broad knowledge of medical terminology.
#1 - There are more sources of mesenchymal stem cells in the body than originally thought. Different sources such as umbilical blood last longer and can regenerate faster. Identifying which stem cells from which part of the body that can most effectively treat certain conditions would produce the best patient outcomes. This saves time and money if these can be identified, this is where PRED comes in. Specific stem cells to treat specific conditions.
#2 - Amniotic fluid (the fluid that surrounds a baby, where the term water breaks comes from) contains mesenchymal stem cells with a marker or identifier. This is easier to obtain than amniotic membrane (the tissues surrounding the amniotic fluid to hold it all in) and is more plentiful. Most prenantal genetic testing comes from amniotic fluid.
#3 - Stem cells can be injected into your veins like a normal IV you would get at a hospital. In medicine, not all substances can cross the blood brain barrier (let’s call it an imaginary wall) it’s like how oil stays on top of water. Mesenchymal stem cells can pass this barrier and get to the site that needs healed in ways other meds may not be able to. They have been shown to help memory and learning deficits. If they could somehow get and fda approved treatment for memory loss patients it would be huge. Although this would probably be years down the road.
#4 - This one had to do with ischemia (blockage) could be used for the heart or brain. Think heart attack or stroke. The embryonic stem cells worked better than the fetal mesenchymal cells. More inflammation was reduced with the embryonic less inflammation - more space- less chance for blockage- better patient outcomes.
I know this just covers the stem cell part of the business which isn’t the only thing pred has going.It appears they are identifying exactly what part of the body you can take a stem cell from to most effectively treat specific conditions.
I still think negotiations with CITIC was/is the biggest possibility for the NASDAQ uplist. Speculating of course.
Re: Management meeting in February.
I'm definitely up for the a trip to Utah in February, deez. Was planning on attending the next meeting anyway.
Anyone with a connection to management
Drop me an email at this throwaway account: ijustwannabeahobo@gmail.com
I'm not a subscriber here so can't PM unless it's on a Friday
Another excellent post Deez. I's like ya' thinkin' man. I say dem' management "bucks" know der stuff, utterwize, dey not have a full antler rack, ya' ere'.
Gotta be in a company like dis fo' dah long haul.
buzzard: Good try, mate, but your message about the negatives is as subjective as all the others (short or long).
Listen folks, how many of you have ever established a working relationship with management of the company you own shares in? I'll take a wild guess: maybe 5%. I say maybe. Could be much less.
I have owned large positions in a few microcap companies and have gone to shareholder meetings and because I've asked Wall Street analyst type questions of them (and they new I was a large shareholder), I was able to maintain contact with one key top management individual who I was able to call now and then for updates. None of it was insider info, but it was info that they don't release to the public for obvious reasons. Those updates gave me confidence in the companies execution and future growth and my confirmed my own DD.
I do not have that relationship with anyone in PRED and that's unfortunate, because I'm in the same boat as the rest of you: living with speculation and heaps of uncertainty and that's 99% of most retail investors. However, I, as well as some good folks here, have done extensive DD and are confident that management is and will continue to execute successfully. Could I be wrong? Absolutely. There's always risk in these type of investments.
So, to the one who feeds on carrion, and to the rest of you, SPECULATION does not translate into what's really going on behind closed doors.
PRED-not being transparent. SPECULATION
Bottom line - their corporate culture is simply disingenuous and potentially very harmful in the future for various reasons. TOTAL SPECULATION
There IR and PR people should be fired. MORE SPECULATION
They and their masters simply disrespect us common shareholders. SPECULATION
they are close to losing a lot of good-will to those who bought in good faith. VERY BAD BUSINESS.
SPECULATION SPECULATION SPECULATION
I do respect the Clinical Team who are trying their best to develop great products.
Really? How do you know this? Have you met them and spoken with them at length?
SPECULATION
It's the very top management and perhaps even some in the Administrative Staff that sadly appear to be really rank and clueless amateurs.
SPECULATION SPECULATION SPECULATION
their erratic, bumbling and know-it-all behavior.
SPECULATION SPECULATION SPECULATION
And don’t any of y’all forget that we have a Float of
35,639,797 as of 06/05/2019. Not sure where we are currently but I’m sure it’s still low which means On significant positive news we’re going to see a pretty significant spike
Definitely under the radar and definitely undervalued. Can see a current run to 52 week high but we’ll definitely need positive news, IMO, to break through.15 let alone.20. Don’t forget we’re a penny stock, so any additional volume and sp run is going to be sold off by the flippers. All that being said, I’ve been long for years and recently accumulated heavily in the .03-.04 range. I’m now in the money and intend on selling a portion in the $.15-$.20 range and then stay long with house money. GLTA
Sure does seem that way. We’ll find out soon enough.
Normally, I would think this was end of day painting the tape, but there was some nice sizable bids in the last hour. Let’s see if there’s follow through tomorrow
market research firm Brightfield Group recently stated a projection that annual sales of CBD in the U.S. will grow from $600 million today to more than $23 billion by 2023.
not sure where you are getting 2 billion.
That’s nearly a 40-fold increase.
According to JAMA Network Open, Google searches for CBD are on pace to rise 118% this year compared to last year.
A recent Gallup study showed that nearly two-thirds of Americans are now familiar with the compound.
investment research firm Cowen & Co. says nearly 7% of Americans are now using CBD.
Excellent additional point, Jim! Let’s hope that demand stays high.
We have functional medicine doctors, naturopaths, chiropractors, many various healthcare practitioners, professional athletes, etc. using and promoting CBD. How in the world can the FDA come in and stop all sales of CBD that are currently being sold? They have to come up with guidelines that allow for companies like CV Sciences to continue doing business. There’s absolutely no way they’ll shut the entire industry down as much as big Pharma would like them to do and are probably pressuring them to do. Maybe this is why it’s taking so long for the guidelines
yep! But will it hold the gains this time. I think not unless there’s some follow up positive news. Still a traders playground
Haha!! I was 17 and pumping gas in 1974 on East 14th Street in San Leandro. Friday and Saturday nights Cruising, hundreds of cars and their young drivers would congregate, with asphalt under their wheels, Wolfman blaring over the radio and a vague promise on their minds. Oh, what an era before cellphones, websites and instant messages.
Love the memories
Let’s see how the shorts spin this PR.
Can’t help but to love the organic growth that’s happening. Long and strong.
“AtozGo is currently adding about 1,000 new customers daily using innovative marketing programs to drive user growth. As it introduces these promotions to more population dense areas of Jakarta, it expects to increase this rate to 2,000-3,000 per day by the end of the first quarter of 2020.“
Oh, wait a moment! I just read a few posts from other messages I had overlooked. My bad! I am now more informed. Yes, this is probably a fake breakout pumpish price action on "no news. Damn management scheming and deceiving us longs again. I'll bet we get another PR that Brad bought another 10k shares catapulting the sp up 30% on the day.
Thinking same. What other reason would there be for his resignation?
Unfortunately, the same scenario at my local Sprouts Farmers Market. Massive display of five other brands with multiple sku’s. Only three roll-ones and two balms on fourth shelf down for CV Science.
What a significant change from three months ago when there was only two or three brands and CVSI center stage.
last message on this topic. assumptions, "especially of a personal nature" are different than opinions. All OPINIONS ALWAYS WELCOMED!
GLTY MATE!
Treading on thin ice here Darth! Keep it neutral and keep it clean brother. It’s unnecessary to make such personal bold assumptions!
“ you just want to get people to buy this stock. Maybe you do mean well, but this company represents your first encounter with these concepts of hemp and extraction etc, so it all comes off to you as new and unique
We all welcome legitimate, well- thought out, unbiased insights and analysis (see jefra’, SL, sleuth, etc. posts) into the CBD/Hemp sector. Notice I didn’t say “opinions.” Opinions get us nowhere!! They, like unsupportable “claims” are a dime-a-dozen and these boards are filled with them. We love factual information and good data with supportable links.
Cheers mate!
“ Maybe there are risks associated with NOT using CBD in the label.”
Ii Have wondered about this.
I was wondering why CV Sciences wasn't on that list. ????
Excellent point, jefra!
Acquiring companies have absolutely no interest in the SP. The bottom line is that the company they're interested in has solid financials, has grown organically in an industry that has been in the grey zone for years, has a valuable IP, has a management team that can weather current choppy waters and can execute their plan going forward.
An acquiring company would have deeper insight into the company than any retail investor could ever have.
But the bigger question is:
WHY WOULD MANAGEMENT WANT TO SELL AT THIS POINT IN TIME?
Has CVSI ever mentioned providing CBG?
Anyone here familiar with the extraction process?
What is CBG and What Are Its Benefits?
Thanks to the 2018 farm bill, hemp is once again being grown on a national scale. And one side-effect of this progressive step has been the rapid growth of public interest in CBD.
CBD has become one of the most searched terms on the internet thanks to its much-publicized health benefits combined with the fact that it’s non-psychotropic, meaning it doesn’t get you high like THC.
But it doesn’t stop there. There are over 100 other cannabinoids – many, if not all, with suspected therapeutic potential – that scientists generally know very little about. One cannabinoid that we do have a few studies on is cannabigerol, or CBG.
Known as the “mother” of all cannabinoids, cannabigerol is widely predicted to be the next big trend in the hemp/cannabis industry. But what do we actually know about CBG?
Looking to try CBG Flowers? Subscribe below to the CBD Flowers Weekly, where this week we are bringing you exclusive deals on CBG flowers!
What is CBG?
CBG has been known since the 1960s when it was found to be the precursor to all other cannabinoids. This is why it’s known as the “mother” of cannabinoids. This fact makes CBG of huge interest to medical researchers and consumers alike.
As CBG converts into all other cannabinoids, plants will have their highest CBG content early in the flowering stage. In most cultivars, if left to fully mature, almost all CBG will be converted into other cannabinoids. However, some cannabis strains – in particular some hemp varieties – naturally produce high amounts of CBG rather than CBD or THC.
CBG vs CBD: What’s the Difference?
As mentioned above, CBD doesn’t have the same psychoactive effects as THC. Rather, it’s reported to relax muscles and calm the mind. This makes it potentially useful for treating anxiety and inflammation. CBD has also been shown to be antipsychotic and have possible anti-cancer properties.
Cannabigerol, meanwhile, is similar to CBD in that it also is non-psychotropic. However, there’s very little research into the effects of CBG on humans, though interest is growing as it is thought by cannabis researchers that many non-psychoactive cannabinoids may have many unique clinical applications.
Effects and Possible Health Benefits
What we have learned from the limited number of studies available is that CBG displays a multitude of potential health benefits. It may have neuroprotective properties, as well as being an antioxidant. It also looks to be antibacterial, antifungal, and anti-inflammatory.
Some research suggests is stimulates appetite and may be useful in the treatment of gastrointestinal disorders and lowering intraocular pressure in glaucoma patients. It also shows promise in fighting cancer, however, more studies are certainly needed before any concrete benefits can be proven.
Is CBG going to be as popular as CBD?
The massive interest is CBD has been unprecedented. While some thought it would just be another fad, demand for CBD products is continuing to grow and the market is predicted to be worth over $20 billion by 2022.
It’s seems unlikely that the CBG market will reach these astronomical figures given CBD’s head start, although there will certainly be an increased demand for many novel cannabinoids over the coming years, with CBG sure to be one of the most popular.
But interest in both CBD and CBG are a part of something bigger. As the public’s perception of cannabis shifts further towards the plant’s therapeutic properties, an entirely new sector focused on nutraceutical consumer products is emerging.
Combined with growing disillusion with mainstream medicine and rising chronic health conditions, the desire for new cannabinoid and botanical-based solutions will only increase. CBD and CBG will both be very important in this new sector.
Summary
Of over 100 cannabinoids produced by the cannabis plant, CBG is one of the most exciting. Partly because it’s the precursor to all other cannabinoids, and partly because early research suggests it may have positive effects in treating a number of conditions.
While CBD has become widely popular over the last couple of years, cannabigerol is still relatively unknown. However, reliable CBG genetics are now becoming more common and farmers are starting to produce premium CBG-rich hemp plants on a wide scale.
Over the coming years, CBG, the mother of all cannabinoids, will play a big part in an even bigger movement that is recognizing the value of cannabinoids and other plant-derived medicines.
LOL! Good one, SL!
Interesting news relevant to the efficacy of synthetic CBD (Epidilolex).
A Second Look At Epidiolex: Does It Actually Work?
https://cbdtesters.co/2019/11/19/a-second-look-at-epidiolex-does-it-actually-work/
Epidiolex is the first and only CBD-based medication to receive FDA approval in the United States, but a recent study suggests it may not be as effective as everyone believed.
Epidiolex was approved in 2018 following three randomized, double-blind, placebo-controlled clinical trials, involving 516 patients with one of two rare seizure disorders: Lennox-Gastaut or Dravet syndrome. However, this new study, published in the British Journal of Clinical Pharmacology, claim that the reduction in seizures attributed to Epidiolex might actually be the result of Clobazam, a drug that’s already used to treat epilepsy.
After taking a second look at the research, it seems that many patients from the trial were also taking Clobazam. “I was flabbergasted when I saw that 50 percent in one study and 60 percent in the other study were actually using this other drug, said Geert Jan Groeneveld in an interview with Analytical Cannabis, the chief scientific officer at the Centre for Human Drug Research in the Netherlands, and lead author of the new study.
According to some documentation, all three of the FDA-cited studies gave the study participants Clobazam to take “concomitantly” with cannabidiol. It’s strange though, that if this what the basis of the research the entire time, why was Epidiolex being prescribed as a stand-alone medication until now?
Now, Groenveld and his colleagues are now calling the effects of just CBD into question. “I’m not saying that I know for a fact that cannabidiol does not have any anti-epileptic effects,” Groeneveld said. “What I am saying is, I can explain the effects that you’ve observed through elevated blood levels of clobazam.”
During their study, Groeneveld and his team replicated the original FDA-trials under the assumption that blood-clobazam levels were around 10 to 20 mg for each participant. They discovered that the drugs work well together and the combination could be better than using each drug individually, however, more research is needed to confirm this.
“[If GW] haven’t shared [the clobazam data] with the FDA, and Epidiolex has been approved in that case, I think it should lead to reassessing whether that was done correctly and whether Epidiolex should be approved for the treatment of epilepsy,” Groeneveld added
Epidiolex was recently approved for research in Japan and use in Europe, so check back with us for more updates.
Hey benjo! I remember you from the CVSI board. Great comparison. I was buying CV Sciences in the .20s through the .60s at the same time I was buying SRNA. Long hold for me like CVSI. GL
Brent purchased another 900.000 shares!!!!!! If that's not a vote of confidence, I don't know what is.
http://ih.advfn.com/stock-market/USOTC/weyland-tech-inc-WEYL/stock-news/81168852/statement-of-changes-in-beneficial-ownership-4
Heaps of BS on this board now that the traders have arrived post-good numbers and higher volume. They’ll soon disappear until the next White Swan event. Until then, Longs stay quiet holding large positions for bigger payoffs later next year or further out.
All IMO.
Lots of new folks here. Welcome! Stay the Course. Excellent management finally executing well. I’ve been here going on three plus years now., although I rarely post. Started accumulating in early 2016 in the .06 -.07 range. Rode it up to .40 plus and then back down. Wasn’t sure they would make it without toxic financing- but they did. Bought big after last quarter’s numbers, again in the .06 - .07 range. After the latest filings, have no intention of selling until .40 plus when I’ll peel off my initial investment and let the rest ride to $1 plus.
GLTA
Yes! November 8. I'll correct my post.
Joseph Dowling accumulated 15,000 shares at $1.65 on November 8
https://ir.cvsciences.com/sec-filings-email/content/0001510964-19-000074/wf-form4_157359269572210.html
let's see some more insiders buying at this discounted price!!
Duffy - a major asset for CV Sciences.
“ Duffy was such a brilliant coup? Because he's a star in the space and has decade long relationships with FDA regulators in the food and dietary supplement space. ”